<DOC>
	<DOCNO>NCT00951613</DOCNO>
	<brief_summary>The purpose study determine whether NK012 safe effective treatment relapse small cell lung cancer .</brief_summary>
	<brief_title>A Study NK012 Patients With Relapsed Small Cell Lung Cancer</brief_title>
	<detailed_description>This Phase II , open label , single arm , multicenter study NK012 patient sensitive relapse SCLC ( least 90 day since first line therapy ) refractory relapse SCLC ( &lt; 90 day since first line therapy ) . NK012 administer intravenous infusion 30 minute every 28 day ( Day 1 cycle ) . Patients screen UGT1A1 polymorphism prior enrollment .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<criteria>1 . Histologically cytologically confirm diagnosis SCLC , relapse first line chemotherapy extensivestage SCLC firstline chemoradiotherapy limitedstage SCLC . 2 . Have receive one , one , prior chemotherapy chemoradiotherapy regimen either newly diagnose extensivestage disease limitedstage disease . 3 . Prior therapy must complete least 4 week prior enrollment patient must recover acute toxicity . 4 . Measurable disease RECIST . 5 . ECOG performance status 02 . 6 . At least 18 year age . 7 . Adequate bone marrow function define absolute neutrophil count great equal 1,500/mm^3 platelet great equal 100,000/mm^3 . 8 . AST ( SGOT ) ALT ( SGPT ) level great 3 x institutional ULN , total bilirubin less equal 1.5 x ULN . 9 . Serum creatinine less equal 1.5 x ULN , creatinine clearance great equal 60 mL/min ( CockcroftGault formula ) patient serum creatinine level &gt; 1.5 x ULN . 10 . Able understand show willingness sign write informed consent document . Exclusion criterion : 1 . Patient Gilbert 's Syndrome . 2 . Prior chemotherapy radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) prior enter study . 3 . Lack recovery adverse effect due agent administer 4 week prior study entry . 4 . Concurrent use investigational agent . 5 . History brain metastasis spinal cord compression , unless irradiate minimum 4 week study entry stable without requirement corticosteroid &gt; 1 week . 6 . Prior exposure topoisomerase 1 inhibitor ( i.e. , irinotecan , topotecan , camptothecin ) . 7 . Concurrent serious infection require parenteral therapy . 8 . Pregnant childbearing potential use method avoid pregnancy . A negative pregnancy test ( urine serum ) must document baseline woman childbearing potential . Patients may breastfeed infant study . 9 . Significant cardiac disease include heart failure meet New York Heart Association ( NYHA ) class III IV definition , history myocardial infarction within one year study entry , uncontrolled dysrhythmias poorly control angina . 10 . History serious ventricular arrhythmia ( VT VF , great equal 3 beat row ) , QTc great equal 450 msec men 470 msec woman , LVEF le equal 40 % MUGA ECHO .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>small cell lung cancer</keyword>
	<keyword>carcinoma , lung</keyword>
	<keyword>Sensitive-relapsed refractory-relapsed small cell lung cancer</keyword>
</DOC>